特立帕肽治疗药物相关性颌骨坏死有效吗?系统综述与荟萃分析
结果显示TPTD联合其他治疗(尤其是抗生素)时完全缓解率更高,且MRONJ 1期患者完全缓解可能性高于3期。
要点
- TPTD联合其他治疗(尤其抗生素)应视为MRONJ的有效治疗模式。
- MRONJ 1期患者完全缓解可能性是3期的1.21倍(CI 1.02-1.43;p<0.023)。
- TPTD联合其他治疗者完全缓解可能性是单用TPTD者的1.21倍(CI 1.40-1.39;p<0.010)。
核心结论
- TPTD联合其他治疗,尤其是抗生素治疗,应被视为MRONJ的有效治疗方式。
主要发现
- 大多数病例为女性(82.0%),平均年龄76.54岁;骨质疏松(76.5%)是使用抗骨吸收药物的主要原因,双膦酸盐(98.1%)最常见。
- MRONJ最常见触发因素为拔牙(61.7%),最常见累及部位为下颌骨(75.8%),平均病程5个月,2期最常见(61.3%)。
- 45.1%病例单用TPTD,总完全缓解率为59.5%;54.9%联合其他治疗(包括手术、抗生素和激光治疗),平均随访8.7个月。
- 泊松回归显示MRONJ 1期患者完全缓解可能性是3期的1.21倍(CI=1.02-1.43;p<0.023)。
- TPTD联合其他治疗者完全缓解可能性是单用TPTD者的1.21倍(CI=1.40-1.39;p<0.010)。
临床怎么用
- 对于MRONJ患者,可考虑使用TPTD联合其他治疗(尤其是抗生素)以提高完全缓解率。
- MRONJ分期较低(1期)的患者可能从TPTD治疗中获益更大。
局限性
- 原文未明确报告纳入研究的偏倚风险、异质性或证据质量评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Considering the lack of studies determining the real TPTD efficacy in individuals who develop MRONJ, our objective was to combine the available data on MRONJ cases treated with TPTD. The findings demonstrated that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ. PURPOSE: To integrate the data published on the effect of teriparatide (TPTD) therapy on cases of medication-related osteonecrosis of the jaws (MRONJ) into a comprehensive analysis of clinical features. METHODS: An electronic search was undertaken in six databases. Descriptive analyses of clinicodemographic data of MRONJ were carried out. Poisson regression was also run to evaluate predictors of total resolution of MRONJ treated with TPTD. RESULTS: Twenty-six publications comprising 111 cases were included. Most reported cases affected female individuals (82.0%) with a mean age of 76.54 years. Osteoporosis (76.5%) represented the main reason for using antiresorptive drugs, with bisphosphonates (98.1%) as the most frequently reported. Comorbidities were commonly present. The most related trigger factor of MRONJ was dental extraction (61.7%). Mandible (75.8%) was the most commonly affected site, with a mean evolution time of 5 months. MRONJ stage 2 (61.3%) was the most prevalent. Regarding TPTD treatment, in 45.1% cases, TPTD was used alone, with the total resolution being observed in 59.5% of the individuals. Associated therapy (54.9%) included surgery, antibiotic therapy, and laser therapy. Mean follow-up was 8.7 months. Poisson regression demonstrated that individuals with MRONJ stage 1 were 1.21 times more likely to present total resolution of osteonecrosis than individuals with MRONJ stage 3 (CI = 1.02-1.43; p < 0.023). Individuals who had undergone treatment with TPTD in association with another therapeutic modality were 1.21 times more likely to present total resolution of osteonecrosis than those who had undergone treatment with TPTD alone (CI = 1.40-1.39; p < 0.010). CONCLUSION: TPTD in combination with another therapy, especially antibiotic therapy, should be considered an effective therapeutic modality for MRONJ.
引用
- Dos Santos Ferreira L, Abreu LG, Calderipe CB, et al. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int. 2021. PMID: 34331067. doi:10.1007/s00198-021-06078-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。